Joana Goncalves, serving as the Chief Medical Officer for Oruka Therapeutics, Inc. (NASDAQ: ORKA), divested 7,000 shares of the company's common stock on July 15, 2026. The aggregate proceeds from these transactions amounted to approximately $603,937. The sales were facilitated through a Rule 10b5-1 trading plan, a pre-arranged framework designed to manage insider transactions, which was established on September 19, 2025. The execution of these sales was preceded by Ms. Goncalves acquiring the requisite shares through the exercise of employee stock options and warrants, an acquisition valued at $51,240.
The disposition of shares occurred across multiple execution points, with transaction prices fluctuating between $83.87 and $87.26 per share. Detailed breakdowns of the sales indicate that 400 shares were sold at a weighted average price of $84.365, within a specific range of $83.87 to $84.57. Subsequently, 2,497 shares were liquidated at a weighted average price of $85.8572, with prices ranging from $85.21 to $86.20. Further transactions included the sale of 3,803 shares at a weighted average price of $86.6764, occurring within a range of $86.21 to $87.04. The final tranche involved 300 shares sold at a weighted average price of $87.2533, with prices tightly clustered between $87.25 and $87.26.
This insider activity unfolds as Oruka Therapeutics has experienced significant equity appreciation, with the stock surging over 500% over the past year. At the time of the report, the shares were trading at $86.65, reflecting a market capitalization of $5.25 billion. Market analysis suggests the stock has delivered substantial returns over the last year. However, comparative valuation metrics indicate that the stock appears overvalued relative to its calculated Fair Value. Investors seeking deeper financial metrics and additional ProTips can access comprehensive data through the platform.
Prior to the sales, Ms. Goncalves acquired the 7,000 shares through the exercise of derivative securities. This acquisition comprised 3,500 shares from an employee stock option exercised at $6.84 per share and an additional 3,500 shares from an employee warrant exercised at $7.80 per share. The vesting schedule for both the option and warrant was structured such that one-quarter of the underlying shares vested on April 18, 2025, with the remaining shares vesting monthly thereafter at a rate of one forty-eighth of the underlying shares per month.
Following these reported transactions, Ms. Goncalves directly holds a total of 32,718 shares of Oruka Therapeutics common stock. The stock's recent performance is reflected in its trading data, which shows a closing price of $86.65, down $0.820 or 0.94%, and an after-hours price of $91.00, up $4.350 or 5.02%.
Concurrent with the insider transaction, Oruka Therapeutics has been the subject of several notable analyst developments. UBS has raised its price target for the company to $130, maintaining a Buy rating driven by optimistic expectations for upcoming efficacy data. Similarly, H.C. Wainwright has reiterated a Buy rating with a $120 price target. This action followed an amendment to Oruka’s licensing agreement with Paragon Therapeutics. The amendment releases rights for IL-23s, enabling both Oruka and Syre to pursue combination and monotherapy developments. Piper Sandler has also reaffirmed an Overweight rating with a $180 price target, citing the same licensing agreement amendment as a positive strategic step. Additionally, H.C. Wainwright highlighted positive results from Oruka’s EVERLAST-A trial, noting that 63.5% of participants achieved complete skin clearance at Week 16. These developments occur amid AbbVie’s announcement to acquire Apogee Therapeutics, which may impact the competitive landscape in the field of inflammatory and immunological diseases.
The intersection of insider selling and analyst bullishness presents a complex dynamic for investors. While the pre-arranged nature of the sales provides a structured context, the substantial stock appreciation raises questions regarding valuation sustainability. The ongoing clinical trial results and licensing agreements remain critical catalysts for the biotech sector.